image credit: Adobe Stock

Biotech Athersys to lay off 70% of staff in cost-cutting effort

June 6, 2022


Athersys’s research efforts are centered around a cell therapy platform it has been studying across a range of conditions, including stroke, respiratory distress and heart attack.

In stroke, Athersys is working with Japan’s Healios, which tested Athersys’ cell therapy as a stroke treatment in a Phase 2/3 trial called TREASURE. The placebo-controlled study was conducted in Japan and enrolled 206 older adults with moderate to moderate-severe ischemic stroke.

Read More on Biopharma Dive